Impact of testosterone therapy on bone turnover markers in obese males with type 2 diabetes and functional hypogonadism.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2022-12-01 DOI:10.1080/13685538.2022.2134338

Kristina Groti Antonič

{"title":"Impact of testosterone therapy on bone turnover markers in obese males with type 2 diabetes and functional hypogonadism.","authors":"Kristina Groti Antonič","doi":"10.1080/13685538.2022.2134338","DOIUrl":null,"url":null,"abstract":"Methods: Fifty-five obese males with type 2 diabetes mellitus and functional hypogonadism participated in a 2-year, double-blind, placebo-controlled study of testosterone undecanoate (TU). Bone turnover markers C-telopeptide of type I collagen (CTX) and procollagen I N-terminal propeptide (PINP) were assessed at baseline, 12 and 24 months. Bone mineral density (BMD) changes were evaluated after 24 months using dual-energy X-ray absorptiometry. Group T (n = 28) received TU both years. Group P (n = 27) received placebo first year and TU second year.Results: CTX decreased in group P from 1055 (676-1344) to 453 (365-665) pmol/L (p < 0.001) and from 897 (679-1506) to 523 (364-835) pmol/L (p < 0.001) in T. PINP decreased by 4.30 ± 8.05 μg/L in group P (p = 0.030) and 4.64 ± 8.86 μg/L in T (p < 0.023) after first year of therapy. No femoral neck BMD changes were observed in 32 patients from both groups (n = 16 per group). Lumbar spine BMD increased (by 0.075 ± 0.114 g/cm2; p = 0.019) in group T following two years of treatment.Conclusions: We observed decreased CTX, decreased PINP and increased lumbar spine BMD after two years of testosterone treatment.Clinical trials: NCT03792321; retrospectively registered trial on 4 January 2019.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13685538.2022.2134338","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 3

Abstract

Methods: Fifty-five obese males with type 2 diabetes mellitus and functional hypogonadism participated in a 2-year, double-blind, placebo-controlled study of testosterone undecanoate (TU). Bone turnover markers C-telopeptide of type I collagen (CTX) and procollagen I N-terminal propeptide (PINP) were assessed at baseline, 12 and 24 months. Bone mineral density (BMD) changes were evaluated after 24 months using dual-energy X-ray absorptiometry. Group T (n = 28) received TU both years. Group P (n = 27) received placebo first year and TU second year.

Results: CTX decreased in group P from 1055 (676-1344) to 453 (365-665) pmol/L (p < 0.001) and from 897 (679-1506) to 523 (364-835) pmol/L (p < 0.001) in T. PINP decreased by 4.30 ± 8.05 μg/L in group P (p = 0.030) and 4.64 ± 8.86 μg/L in T (p < 0.023) after first year of therapy. No femoral neck BMD changes were observed in 32 patients from both groups (n = 16 per group). Lumbar spine BMD increased (by 0.075 ± 0.114 g/cm²; p = 0.019) in group T following two years of treatment.

Conclusions: We observed decreased CTX, decreased PINP and increased lumbar spine BMD after two years of testosterone treatment.

Clinical trials: NCT03792321; retrospectively registered trial on 4 January 2019.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

睾酮治疗对伴有2型糖尿病和功能性性腺功能减退的肥胖男性骨转换标志物的影响。

方法:55名患有2型糖尿病和功能性性腺功能减退症的肥胖男性参与了一项为期2年的双盲、安慰剂对照研究。在基线、12和24个月时评估骨转换标志物I型胶原c端肽(CTX)和I型前胶原n端前肽(PINP)。24个月后采用双能x线骨密度仪评估骨密度变化。T组(n = 28)每年均接受TU治疗。P组(n = 27)第一年使用安慰剂，第二年使用TU。结果:P组CTX由1055(676-1344)降至453 (365-665)pmol/L (P P = 0.030)， T组为4.64±8.86 μg/L (P n = 16 /组)。腰椎骨密度增高(0.075±0.114 g/cm2;p = 0.019)。结论:经过两年的睾酮治疗，我们观察到CTX降低，PINP降低，腰椎骨密度增加。临床试验:NCT03792321;回顾性注册试验于2019年1月4日进行。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊